ES8404372A1 - Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento - Google Patents

Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento

Info

Publication number
ES8404372A1
ES8404372A1 ES524511A ES524511A ES8404372A1 ES 8404372 A1 ES8404372 A1 ES 8404372A1 ES 524511 A ES524511 A ES 524511A ES 524511 A ES524511 A ES 524511A ES 8404372 A1 ES8404372 A1 ES 8404372A1
Authority
ES
Spain
Prior art keywords
inactivator
eventually
dissolution
free
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES524511A
Other languages
English (en)
Spanish (es)
Other versions
ES524511A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES524511A0 publication Critical patent/ES524511A0/es
Publication of ES8404372A1 publication Critical patent/ES8404372A1/es
Expired legal-status Critical Current

Links

Classifications

    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005—Stabilisers against oxidation, heat, light, ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
ES524511A 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento Expired ES8404372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung

Publications (2)

Publication Number Publication Date
ES524511A0 ES524511A0 (es) 1984-04-16
ES8404372A1 true ES8404372A1 (es) 1984-04-16

Family

ID=6169724

Family Applications (2)

Application Number Title Priority Date Filing Date
ES524511A Expired ES8404372A1 (es) 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento
ES525361A Granted ES525361A0 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES525361A Granted ES525361A0 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Country Status (9)

Country Link
US (1) US4915945A (enExample)
EP (1) EP0101935B1 (enExample)
JP (2) JPS5944320A (enExample)
AT (1) ATE19590T1 (enExample)
AU (1) AU564614B2 (enExample)
CA (1) CA1223201A (enExample)
DE (2) DE3228502A1 (enExample)
ES (2) ES8404372A1 (enExample)
ZA (1) ZA835561B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376367B (de) * 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
FR2618784B1 (fr) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
JP2729484B2 (ja) * 1988-04-28 1998-03-18 株式会社ミドリ十字 アンチトロンビン−▲ｉｉｉ▼の精製方法
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
ES2171465T3 (es) * 1993-09-01 2002-09-16 Sanquin Bloedvoorziening Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
DK2793935T3 (en) 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
KR20160026905A (ko) 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CN110769848A (zh) 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
JP7410019B2 (ja) 2017-09-15 2024-01-09 シーダーズ－サイナイ メディカル センター 臓器移植患者における臓器機能を改善するための方法
WO2020079108A1 (en) 2018-10-17 2020-04-23 Csl Behring Gmbh Process for purifying c1-inh
CN114096558B (zh) 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
KR20230110563A (ko) 2020-11-20 2023-07-24 체에스엘 베링 게엠베하 항체 매개 거부 반응의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322139B2 (enExample) * 1973-11-15 1978-07-06
NL7602846A (nl) * 1976-03-18 1977-09-20 Leuven Res & Dev Vzw Antiplasmine en een antiserum daartegen.
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution

Also Published As

Publication number Publication date
AU564614B2 (en) 1987-08-20
AU1745183A (en) 1984-02-02
CA1223201A (en) 1987-06-23
JPH0480886B2 (enExample) 1992-12-21
ES8501413A1 (es) 1984-11-16
ZA835561B (en) 1984-03-28
DE3363395D1 (en) 1986-06-12
DE3228502A1 (de) 1984-02-02
EP0101935B1 (de) 1986-05-07
JPH07103044B2 (ja) 1995-11-08
JPH05306236A (ja) 1993-11-19
JPS5944320A (ja) 1984-03-12
ATE19590T1 (de) 1986-05-15
US4915945A (en) 1990-04-10
EP0101935A1 (de) 1984-03-07
ES525361A0 (es) 1984-11-16
ES524511A0 (es) 1984-04-16

Similar Documents

Publication Publication Date Title
ES8404372A1 (es) Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento
ES2004486A4 (es) Procedimiento para la obtencion de nuevas diamidas del acido dicarboxilico, membrana selectiva de iones para la determinacion de la concentracion de iones de litio y dispositivo de ensayo que las contienen. .
DK0447585T3 (da) Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat
RO80120A (ro) Procedeu de preparare a metacrolinei si acidului metacrilic
BE901792A (fr) Solution ophtalmique et son procede de preparation.
BE876262A (fr) Procede de preparation de l'acide (s,5s)- -amino-3-chloro-isoxazoline-5-acetique, nouveaux analogues de cet acide, et preparation de ces analogues
FR2341552A1 (fr) Procede de preparation d'acide methacrylique
JPS5630925A (en) Purification of human growth hormone
FR2554809B1 (fr) Procede de preparation de l'acide acrylique
ES8603268A1 (es) Un metodo de preparar un complejo de yodo con polidextrosa
ES8501234A1 (es) Procedimiento para producir preparaciones farmaceuticas que contienen como substancias activas derivados de polialquilenglicol.
MA18955A1 (fr) Procede de recuperation globale de l'uranium,des terres rares,du thorium et de l'yttrium contenus dans une solution acide
OA06490A (fr) Procédé de purification de l'acide phosphorique.
ATE48595T1 (de) Verfahren zur rueckgewinnung von 4,4'dihydroxydiphenylsulfonaus einer isomermischung.
IT1122151B (it) Sistema di sacchetti per la coltura di sangue
ES2046999T3 (es) Un metodo para la purificacion de interferon.
PT85278A (fr) Procede de preparation d:une fraction immunogene active a liegard des bilharzioses et de compositions immunisantes la contenant
RO70958A (ro) Procedeu de preparare a unor esteri ai acidului o-etil-s-n-propil-o-2,2,2-trihaloetil tiono(tiol)fosforic
RO93391B (ro) Procedeu pentru prepararea unor saruri de dobutamina
AR241134A2 (es) Un procedimiento para preparar w-lactamas
BE865774A (fr) Procede de preparation de l'acide 1-amino-8-naphtol-3,6-disulfonique (acide "h")
MA19328A1 (fr) Procede de recuperation de l'uranium (vi) present dans des solutions d'acide phosphorique .
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
ES423697A1 (es) Un procedimiento para preparar una solucion de haptoglobinade suero humano.
Hosick et al. The unexpected incorporation of unbound iodide-131 into the non-radioactive hippuran molecule

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20040916